鼠伤寒沙门菌fnr、arcA和fliC三基因突变株的免疫原性与保护效力
本研究构建了鼠伤寒沙门菌三基因突变株SLT39(ΔfnrΔarcAΔfliC),其在小鼠组织中定植缺陷且毒力较野生株降低约10^4倍。小鼠间隔28天两次免疫(10^7或10^8 CFU)后,SLT39诱导显著血清IgG、IgG1、IgG2a及粪便IgA应答,10^8 CFU组十二指肠和盲肠IgA更高。致死剂量攻击后,10^8 CFU组全部存活,10^7 CFU组80%存活,组织载量显著降低。
要点
- SLT39三基因突变株毒力较野生株降低约10^4倍,具高度减毒特性。
- 两次免疫后SLT39诱导显著血清IgG和黏膜IgA应答,10^8 CFU组黏膜IgA更高。
- 致死攻击后10^8 CFU组全部存活,10^7 CFU组80%存活,组织载量显著降低。
核心结论
- SLT39(ΔfnrΔarcAΔfliC)是预防同源鼠伤寒沙门菌感染的潜在减毒活疫苗候选株。
研究设计与样本
- 构建鼠伤寒沙门菌三基因突变株SLT39,在小鼠中评估减毒程度、定植能力、免疫原性和致死攻击保护效力。
主要发现
- SLT39在小鼠组织中存在定植缺陷,毒力较野生株降低约10^4倍。
- 小鼠间隔28天两次免疫10^7或10^8 CFU SLT39后,血清总IgG、IgG1、IgG2a和粪便IgA应答显著高于模拟免疫组。
- 10^8 CFU组十二指肠和盲肠IgA水平高于10^7 CFU组。
- 致死剂量野生株攻击后,SLT39免疫组小鼠Peyer斑、脾和肝的细菌载量显著低于对照组。
- 10^8 CFU组全部小鼠存活,10^7 CFU组80%小鼠存活。
临床怎么用
- SLT39作为减毒活疫苗候选株,可能用于预防同源鼠伤寒沙门菌感染,还需进一步临床前和临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Salmonella enterica serovar Typhimurium is a major food-borne pathogen that can cause self-limited gastroenteritis or life-threatening invasive diseases in humans. There is no licensed S. Typhimurium vaccine for humans to date. In this study, we attempted to construct a live attenuated vaccine strain of S. Typhimurium based on three genes, namely, the two global regulator genes fnr and arcA and the flagellin subunit gene fliC. The S. Typhimurium three-gene mutant, named SLT39 (ΔfnrΔarcAΔfliC), exhibited a high level of attenuation with a colonization defect in mouse tissues and approximately 104-fold decreased virulence compared with that of the wild-type strain. To evaluate the immunogenicity and protection efficacy of STL39, mice were inoculated twice with a dose of 107 CFU or 108 CFU at a 28-day interval, and the immunized mice were challenged with a lethal dose of the wild-type S. Typhimurium strain one month post second immunization. Compared with mock immunization, SLT39 immunization with either dose elicited significant serum total IgG, IgG1 and IgG2a and faecal IgA responses against inactivated S. Typhimurium antigens at a comparable level post second immunization, whereas the 108 CFU group induced higher levels of duodenal and caecal IgA than the 107 CFU group. Furthermore, the bacterial loads in mouse tissues, including Peyer's patches, spleen and liver, significantly decreased in the two SLT39 immunization groups compared to those in the control group post challenge. Additionally, all mice in the SLT39 (108 CFU) group and 80% of the mice in the SLT39 (107 CFU) group survived the lethal challenge, suggesting full protection and 80% protection efficacy, respectively. Thus, the S. Typhimurium fnr, arcA and fliC mutant proved to be a potential attenuated live vaccine candidate for prevention of homologous infection.
引用
- Zhao X, Zeng X, Dai Q, et al. Immunogenicity and protection efficacy of a Salmonella enterica serovar Typhimurium fnr, arcA and fliC mutant. Vaccine. 2020. PMID: 33341307. doi:10.1016/j.vaccine.2020.12.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。